FDA Has Granted Type B/Breakthrough Guidance Meeting To Bioxcel Therapeutics Regarding The Company's TRANQUILITY Trial Program, Which Is Scheduled For October 11, 2023 - 8K
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted a Type B/Breakthrough Guidance meeting to Bioxcel Therapeutics for its TRANQUILITY trial program, scheduled for October 11, 2023, according to an 8K filing.
August 22, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bioxcel Therapeutics has been granted a Type B/Breakthrough Guidance meeting by the FDA for its TRANQUILITY trial program. This could potentially accelerate the development and approval process of the company's product.
The FDA's Type B/Breakthrough Guidance meeting is a significant regulatory milestone that could potentially accelerate the development and approval process of Bioxcel's product. This news is highly relevant and important for BTAI as it directly impacts the company's product pipeline and future revenue potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100